Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
And four other potential targets that could make sense for the beleaguered group.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.